[High-dose methylprednisolone in the treatment of terminal cancer patients].
High-dose corticoid therapy was assessed in 36 patients with end-stage cancer of various different types. These patients were compared with a control group of patients with terminal cancer on a conventional palliative regimen without corticoid therapy. Euphoria, a decrease in the required dose of analgetic and psychopharmacological drugs and an anti-inflammatory effect in cases with peritumorous oedema were observed in 27 patients.
D001943:Breast Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006801:Humans; D007273:Injections, Intramuscular; D008175:Lung Neoplasms / Q000188:drug therapy; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D010024:Osteoporosis / Q000139:chemically induced; D010039:Otorhinolaryngologic Neoplasms / Q000188:drug therapy; D010437:Peptic Ulcer / Q000139:chemically induced; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced
D008775:Methylprednisolone
Hochdosiertes Methylprednisolon in der Behandlung des terminalen Karzinompatienten.